How Softgel Formulation Design Affects Product Stability and Performance
Author : Chemical Bull | Published On : 30 Jul 2026
Softgel capsules are widely used in pharmaceutical manufacturing because they can deliver liquid and semi-solid fills in a convenient oral dosage form. Their smooth surface, ease of swallowing and ability to contain oily or difficult-to-compress materials make them suitable for a range of formulations.
However, softgel development requires careful control of both the fill formulation and the capsule shell. A stable fill is not enough if it weakens the shell, causes leakage or changes drug release. Likewise, a strong shell cannot compensate for poor content uniformity, crystallisation or ingredient separation inside the capsule.
Manufacturers working with surface-active pharmaceutical ingredients can review the role of Docusate Sodium in softgels and oral pharmaceutical dosage forms to understand how formulation behaviour can vary across different delivery systems.
Why Softgel Formulation Requires Special Attention
A softgel is made from two closely interacting systems: the capsule shell and the internal fill. The shell generally contains gelatin or another suitable film-forming material, water and a plasticiser. The fill may contain oils, solvents, suspending agents, active ingredients and stabilising materials.
These two systems remain in contact throughout manufacturing and storage. Ingredients can migrate between the fill and shell, causing changes in flexibility, appearance, seal strength and release performance.
For this reason, softgel development must evaluate the complete capsule rather than studying the fill and shell separately.
Fill Composition and Solubility
The active or functional ingredient must remain uniformly distributed within the fill. Depending on its characteristics, it may be dissolved, dispersed or suspended in a suitable vehicle.
A dissolved ingredient can provide better content uniformity, but it may crystallise if temperature or solvent balance changes. A suspended ingredient may remain physically stable only when particle size, viscosity and sedimentation are properly controlled.
The fill vehicle should be selected according to ingredient solubility, chemical stability and compatibility with the shell. Oils, polyethylene glycols and other approved pharmaceutical vehicles may be considered depending on the formulation requirement.
The selected system should also remain stable during encapsulation, storage and transport.
Shell and Fill Compatibility
Shell compatibility is one of the most important parts of softgel formulation. Some solvents can draw water from the shell, while others can migrate into it and make the capsule too soft.
Excessive moisture loss may make the shell brittle and prone to cracking. Excessive moisture absorption can cause deformation, sticking or weak seals.
The pH and chemical nature of the fill can also influence gelatin stability. Reactive ingredients may affect shell strength, colour or dissolution behaviour over time.
Compatibility studies should therefore monitor capsule appearance, shell flexibility, leakage and drug release under different storage conditions.
Moisture Migration
Softgel shells contain controlled amounts of water. During storage, moisture may move between the shell, fill and external environment.
The direction and degree of migration depend on the water activity of each component and the barrier properties of the packaging. This movement can change capsule hardness, fill viscosity and product stability.
High-humidity storage may soften the capsule, while dry conditions may make it brittle. Manufacturers should evaluate the product under the temperature and humidity conditions expected in the intended market.
Suitable packaging can reduce moisture exchange and support shelf-life performance.
Fill Viscosity and Encapsulation
Fill viscosity affects pumping, dosing and encapsulation accuracy. A fill that is too thin may leak or move excessively during sealing. A fill that is too thick may create inconsistent dosing or processing difficulties.
The target viscosity should allow smooth transfer through manufacturing equipment while maintaining ingredient uniformity.
Temperature control is also important because many fill vehicles change viscosity when heated or cooled. If the encapsulation temperature differs significantly from laboratory conditions, the fill may behave differently during commercial production.
Pilot-scale testing helps determine whether the formulation can be processed consistently.
Preventing Ingredient Separation
Suspended or multi-phase fills may separate during holding or encapsulation. Heavy particles can settle, while lighter materials may rise to the surface.
Separation can produce content variation between capsules. It can also lead to inconsistent appearance or drug-release behaviour.
Formulators may use viscosity-building or suspending ingredients to slow particle movement. The mixing system should maintain uniformity without introducing excessive air.
Holding time before encapsulation should be established during process development. Long delays can increase the risk of settling or crystallisation.
Foaming and Air Entrapment
Surface-active ingredients may generate foam during fill preparation. Air bubbles can interfere with volume measurement, pumping and capsule filling.
Entrapped air may also affect capsule appearance or create oxidation risks for sensitive ingredients.
Mixing speed, vessel design and ingredient-addition order should be optimised to minimise aeration. Deaeration may be required before encapsulation, depending on the formulation.
Foaming behaviour should be studied during scale-up because larger equipment can introduce more air than laboratory mixing.
Chemical Stability
Softgel fills may contain ingredients sensitive to oxygen, moisture, heat or light. Chemical degradation can reduce assay and increase impurities during storage.
Antioxidants, chelating agents or protective packaging may be considered where technically and regulatorily appropriate. The fill vehicle itself should also be evaluated for oxidation or interaction with the active ingredient.
Stability studies should monitor assay, degradation products, colour, odour and physical changes. Testing should be performed in the final proposed packaging because the container can significantly affect product stability.
Drug Release and Dissolution
The softgel must release its contents consistently after administration. Shell composition, storage conditions and fill properties can influence rupture and dissolution.
A capsule that becomes excessively hard during storage may show delayed opening. Cross-linking or shell changes can also affect dissolution behaviour.
The fill formulation may influence how quickly the ingredient disperses after the shell breaks. Poorly soluble ingredients may still require wetting, solubilisation or dispersion support.
Dissolution testing should be included throughout development and stability studies to confirm consistent release over the product’s shelf life.
Scale-Up and Manufacturing Control
A softgel formulation that performs well in the laboratory may behave differently on commercial equipment. Mixing, transfer, heating, holding and encapsulation times are usually longer at scale.
Manufacturers should establish controls for fill temperature, viscosity, mixing speed, holding time and encapsulation conditions. In-process testing may include fill uniformity, capsule weight, seal integrity and appearance.
Scale-up batches should be evaluated under realistic production conditions before final process validation.
Quality and Sourcing Considerations
Raw materials used in softgel production should meet the required pharmaceutical specification. Buyers should review assay, purity, moisture, impurity profile and batch consistency where applicable.
The Certificate of Analysis, Safety Data Sheet and product specification should be evaluated before approval. Storage conditions, retest period, packing and supply continuity should also be considered.
Materials with the same chemical name can differ in physical form, purity and processing behaviour. Application testing remains necessary even when an ingredient meets its basic specification.
Conclusion
Successful softgel formulation depends on the interaction between the internal fill, capsule shell, manufacturing process and final packaging. Solubility, viscosity, moisture migration, shell compatibility and ingredient stability must be controlled together.
Manufacturers should confirm performance through laboratory development, pilot trials, scale-up studies and stability testing. A well-designed softgel system supports uniform dosing, reliable sealing and consistent release throughout the intended shelf life.
For pharmaceutical ingredient requirements, contact Chemical Bull with the required grade, quantity, dosage-form application, packing preference and delivery destination to receive specifications, documentation and commercial supply support.
